The invention provides non-naturally occurring microbial organisms containing a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms selectively produce a fatty alcohol, fatty aldehyde or fatty acid of a specified length. Also provided are non-naturally occurring microbial organisms having a fatty alcohol, fatty aldehyde or fatty acid pathway, wherein the microbial organisms further include an acetyl-CoA pathway. In some aspects, the microbial organisms of the invention have select gene disruptions or enzyme attenuations that increase production of fatty alcohols, fatty aldehydes or fatty acids. The invention additionally provides methods of using the above microbial organisms to produce a fatty alcohol, a fatty aldehyde or a fatty acid.

The present invention provides, in part, formulations comprising an alkaline phosphatase. Particularly, modified-release formulations comprising an alkaline phosphatase are provided, which release a substantial amount of the alkaline phosphatase in the intestines. Therapeutic uses of the alkaline phosphatase formulations are also provided.

The present disclosure relates to compositions of immobilized enzymes on the surface of achromosomal and/or anucleate cells and uses thereof. In particular, the present disclosure provides genetically engineered minicells with enzymes self-assembled on their surface. The immobilized enzymes on the surface of achromosomal and/or anucleate minicells, has agricultural, industrial, and environmental applications due to their improved stability durability and, reusability. Also, provided are methods for producing and purifying enzyme-immobilized minicells.

The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment—Gait (mPOMA-G) analysis and score.

The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.

The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.

This invention demonstrates that topically applied placental alkaline phosphatase dispersed in Vaselinum cholesterinatum promotes scar-free healing of acne vulgaris of bacterial origin. Other inflammatory skin conditions caused by bacterial infection and improved by placental alkaline phosphatase include nail infections as well as infections of non-healing diabetic wounds, puncture wounds, surgical wounds and incisions, burns, abrasions, lacerations, ulcers, gum disease, skin tears, or wounds caused by bites or stings. Placental alkaline phosphatase was also found to promote healing of skin lesions, with or without co-administering an antiviral drug, caused by reactivated Varicella zoster (Shingles), Herpes Simplex Virus-1 (oral herpes), or Herpes Simplex Virus 2 (vaginal/genital herpes). In all of these cases, placental alkaline phosphatase was found to significantly reduce irritation or pain associated with bacterial or viral infection and resulting skin damage.

The problem of detecting whether a urine sample is true human urine or a counterfeit urine product is solved by the use of reagent systems that detect two markers normally present in human urine. The markers acid phosphatase and alkaline phosphatase catalyze the substrates thymolphthalein monophosphate and p-nitrophenol phosphate, respectively. These substrates are formulated as spot tests on a dip stick or as reagents for use in automated chemical analyzers. The presence of the markers can be qualitatively detected by color-changes in the sample, formed by the pH-specific chromogens that result from catalysis of the substrates with the markers. The control reagent can further indicate whether a counterfeit urine product contains one or both of the chromogens.

Devices, assays and methods for detecting analytes in a sample are provided. Biosensor devices include a biosensor interface that includes enzyme-conjugated molecules, antibodies and an enzyme driven redox cycle coupled to an electrically conductive electrode for signal amplification. The biosensor devices are easily adaptable to a variety of assay formats, a variety of target analytes and provide real-time measurements combined with high sensitivity and high specificity for the analyte.